Statin-Associated Muscle Symptoms and Myotoxicity: A Clinically Oriented Narrative Review with a Practical...

Area of Science:

• Pharmacology
• Clinical Medicine
• Toxicology

Background:

• Muscle symptoms are a common concern with statin use, but precise terminology is often lacking.
• Distinguishing between subjective myalgia and objective myopathy is crucial for accurate diagnosis and management.
• Statin-associated muscle symptoms (SAMS) encompass a spectrum from mild aches to severe myotoxicity.

Purpose of the Study:

• To synthesize current evidence on statin-associated muscle symptoms and severe myotoxicity.
• To propose a practical algorithm for the prevention, evaluation, and management of SAMS.
• To standardize terminology for muscle events related to statin therapy.

Main Methods:

• A narrative review of literature from January 2021 to April 2026 was conducted.
• Searches included PubMed, Google Scholar, and major society guidelines.
• 55 verifiable sources covering SAMS, myopathy, rhabdomyolysis, immune-mediated myopathy, nocebo effects, and management were analyzed.

Main Results:

• Blinded studies show a small excess of muscle pain with statins, primarily in the first year; most symptoms are not pharmacologically induced.
• N-of-1 and crossover trials suggest a significant nocebo/drucebo effect contributing to reported symptoms.
• Severe toxicity is rare but can occur with increased statin exposure due to dose, drug interactions, or patient factors.

Conclusions:

• Reported SAMS are common, but confirmed statin-induced muscle injury is less frequent than often assumed.
• Permanent statin discontinuation should be reserved for carefully assessed cases of genuine toxicity.
• A structured management approach, including risk assessment and dechallenge/rechallenge, preserves cardiovascular benefits while managing muscle symptoms.